Is Gracell Biotechnologies Inc. (GRCL) a Buy, Sell, or Hold?
Gracell Biotechnologies Inc.
NASDAQ:GRCL
$10.25 USD
$0.01 (0.05%)
- Volume
- 6.37M
- Average Volume
- 1.61M
- Market Capitalization
- $197.97M
- P/E Ratio
- -1.55
- Dividend Yield
- 0.00%
- Price Target
- $6.00
- Year High
- $10.44
- Year Low
- $1.40
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.78
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Wei Cao BM, |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | GRCL |
| CUSIP | 38406L103 |
| CIK | 0001826492 |
| Web | https://www.gracellbio.com |
| Phone | 86 512 6262 6701 |
| Currency | USD |
| Employees | 314 |
| Country | CN |
Liquidity
| Debt-to-Equity Ratio | 0.13 |
| Payout Ratio | 0.00 |
| Current Ratio | 6.78 |
| Quick Ratio | 6.78 |
| Cash Ratio | 6.59 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -268.73 |
| Price / Cash Flow | -0.37 |
| Price / Book | 0.68 |
Price Target and Rating
| Average Stock Price Forecast | $6.00 |
| High Stock Price Forecast | $6.00 |
| Low Stock Price Forecast | $6.00 |
| Forecast Upside/Downside | 70.83% |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 8 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-44.85 |
| Trailing P/E Ratio | -1.55 |
| PEG Ratio | -0.08 |
| P/E Growth | -0.08 |
| Net Income | $-607.51M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -37.93% |
| Return on Assets | -36.68% |
Financials Score
| AltmanZ Score | 1.50 |
| Piotroski Score | 3.00 |
| Working Capital | 1.54B |
| Total Assets | 1.89B |
| Ebit | -578.82M |
| Market Cap | 1.34B |
| Total Liabilities | 268.86M |
Poll Results
About Gracell Biotechnologies Inc. (NASDAQ:GRCL) Stock
Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of cell-based therapies, primarily for cancer treatment, within the People's Republic of China. The company's leading investigational therapies include: GC012F: A FasTCAR-enhanced autologous CAR-T product designed to target both BCMA and CD19, currently undergoing Phase I clinical trials for multiple myeloma. GC019F: A FasTCAR-enabled CD19-directed autologous CAR-T therapy, which is progressing through Phase I trials for adult B-cell acute lymphoblastic leukemia (B-ALL) and is also in preclinical development for relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL). GC027: A TruUCAR-powered allogeneic CAR-T product targeting CD7, presently in Phase I clinical dev ... elopment for adult T-cell acute lymphoblastic leukemia. Additionally, Gracell's pipeline features: GC007g: A donor-derived allogeneic CAR-T cell therapy directed at CD19, currently in a Phase 1/2 registrational study for r/r B-ALL. GC502: An off-the-shelf, TruUCAR-enabled allogeneic CAR-T candidate engineered to target both CD19 and CD7, which is in Phase I trials for B-cell malignancies. Beyond these, Gracell maintains a broader portfolio of earlier-stage therapeutic candidates addressing diverse oncological conditions, including ovarian cancer, breast cancer, peripheral T cell lymphoma (a subtype of NHL), and T cell lymphoblastic leukemia. Established in 2017, the company's headquarters are situated in Suzhou, China.
Frequently Asked Questions
-
What is the current Gracell Biotechnologies Inc. (GRCL) stock price?
-
Gracell Biotechnologies Inc.(NASDAQ:GRCL) stock price is $10.25 in the last trading session. During the trading session, GRCL stock reached the peak price of $10.435 while $1.4 was the lowest point it dropped to. The percentage change in GRCL stock occurred in the recent session was 0.05% while the dollar amount for the price change in GRCL stock was $0.01.
-
GRCL's industry and sector of operation?
-
The NASDAQ listed GRCL is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of GRCL?
-
Erin Li | Executive Officer
Wei Cao | Founder, Chairman & Chief Executive Officer
Wendy Li | Chief Medical Officer
Yili Xie | Chief Financial Officer
Samuel Suhua Zhang | Chief Business Officer -
How many employees does GRCL have?
-
Number of GRCL employees currently stands at 314. GRCL operates from Building 12, Block B, Suzhou, None 215123, CN.
-
Link for GRCL official website?
-
Official Website of GRCL is: https://www.gracellbio.com
-
How do I contact GRCL?
-
GRCL could be contacted at phone #86 512 6262 6701 and can also be accessed through its website. GRCL operates from Building 12, Block B, Suzhou, None 215123, CN.
-
How many shares of GRCL are traded daily?
-
The average number of GRCL shares traded daily for last 3 months was 1.61M.
-
What is the market cap of GRCL currently?
-
The market value of GRCL currently stands at $197.97M with its latest stock price at $10.25